

FOR IMMEDIATE RELEASE

CliniDATA Source Is Born

Etreby Computer Company spins off its Clinical Database Operations

January 1, 2000

CliniDATA Source is a new name to the healthcare industry but the products and services it provides have been in existence for approximately two decades and are currently being used in over 1,000 U. S. pharmacies from coast to coast. We are targeting healthcare information system developers with a set of high quality, comprehensive drug information databases and value-added clinical intelligence software drivers ready for integration into their application software systems.

CliniDATA Source is poised for a leading position in this industry by serving its clients' needs in an honest, compassionate and caring way. The fact that our parent company is a healthcare software developer provides us with this unique understanding of our clients' business problems and challenges.

We are committed to fulfilling our clients' as well as our staff members' expectations of the highest quality products and services delivered in an open, caring, and team oriented environment.

CliniDATA Source-- A Wholly Owned Subsidiary of Etreby Computer Company, Inc.

Etreby Computer Company is a leading healthcare software developer established in 1981. Bill Etreby, PharmD., co-founder and CEO, is a renowned clinical pharmacist who specializes in information technology. Under his leadership, Etreby Computer Company has been providing more than 1,000 clients with internally developed clinical information for DUR screening. Etreby Computer Company is also known for its well recognized ApotheCare-2000. It is by far the most sophisticated and highly acclaimed disease management software system available.

CliniDATA Source is established as an independent concern. It will continue to have strong ties to, and benefit from, Etreby's technical resources.

This release contains certain "forward-looking statements," relating to the Company's business, which can be identified by the use of forward-looking terminology such as "may," "promising," or similar expressions, or by discussions of strategy, plans or intentions. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Any such commercialization can be affected by, among other things, uncertainties relating to product development, regulatory actions or delays or government regulation generally, the ability to obtain or maintain patent or other proprietary intellectual property protection, lack of pharmaceutical companies to provide pricing information, competition in general and other risks and factors referred to in Form 20-F of the Securities and Exchange Commission of the United States.